Cargando…

A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics

Peptides have great potential as therapeutic agents, however, their clinic applications are severely hampered by their instability and short circulation half-life. Zero-order release carriers could not only extend the circulation lifetime of peptides, but also maintain the plasma drug level constant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ya-Nan, Xu, Xiaoyu, Wen, Na, Song, Rui, Meng, Qingbin, Guan, Ying, Cheng, Siqi, Cao, Danni, Dong, Yansheng, Qie, Jiankun, Liu, Keliang, Zhang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514143/
https://www.ncbi.nlm.nih.gov/pubmed/28717204
http://dx.doi.org/10.1038/s41598-017-05898-6
_version_ 1783250789361254400
author Zhao, Ya-Nan
Xu, Xiaoyu
Wen, Na
Song, Rui
Meng, Qingbin
Guan, Ying
Cheng, Siqi
Cao, Danni
Dong, Yansheng
Qie, Jiankun
Liu, Keliang
Zhang, Yongjun
author_facet Zhao, Ya-Nan
Xu, Xiaoyu
Wen, Na
Song, Rui
Meng, Qingbin
Guan, Ying
Cheng, Siqi
Cao, Danni
Dong, Yansheng
Qie, Jiankun
Liu, Keliang
Zhang, Yongjun
author_sort Zhao, Ya-Nan
collection PubMed
description Peptides have great potential as therapeutic agents, however, their clinic applications are severely hampered by their instability and short circulation half-life. Zero-order release carriers could not only extend the circulation lifetime of peptides, but also maintain the plasma drug level constant, and thus maximize their therapeutic efficacy and minimize their toxic effect. Here using PEGylated salmon calcitonin (PEG-sCT)/tannic acid (TA) film as an example, we demonstrated that hydrogen-bonded layer-by-layer films of a PEGylated peptide and a polyphenol could be a platform for zero-order peptide release. The films were fabricated under mild conditions. The second component, TA, is a natural product and presents potential therapeutic activities itself. Unlike common carriers, the new carrier releases the peptide via gradual disintegration of the film because of its dynamic nature. The release of PEG-sCT follows a perfect zero-order kinetics without initial burst release. In addition the release rate could be tuned via external stimuli, such as pH and temperature. When implanted in rats, the films could remain the plasma level of PEG-sCT constant over an extended period. Accordingly, the serum calcium level was reduced and maintained constant over the same period, suggesting an improved therapeutic efficacy of the released drug.
format Online
Article
Text
id pubmed-5514143
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55141432017-07-19 A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics Zhao, Ya-Nan Xu, Xiaoyu Wen, Na Song, Rui Meng, Qingbin Guan, Ying Cheng, Siqi Cao, Danni Dong, Yansheng Qie, Jiankun Liu, Keliang Zhang, Yongjun Sci Rep Article Peptides have great potential as therapeutic agents, however, their clinic applications are severely hampered by their instability and short circulation half-life. Zero-order release carriers could not only extend the circulation lifetime of peptides, but also maintain the plasma drug level constant, and thus maximize their therapeutic efficacy and minimize their toxic effect. Here using PEGylated salmon calcitonin (PEG-sCT)/tannic acid (TA) film as an example, we demonstrated that hydrogen-bonded layer-by-layer films of a PEGylated peptide and a polyphenol could be a platform for zero-order peptide release. The films were fabricated under mild conditions. The second component, TA, is a natural product and presents potential therapeutic activities itself. Unlike common carriers, the new carrier releases the peptide via gradual disintegration of the film because of its dynamic nature. The release of PEG-sCT follows a perfect zero-order kinetics without initial burst release. In addition the release rate could be tuned via external stimuli, such as pH and temperature. When implanted in rats, the films could remain the plasma level of PEG-sCT constant over an extended period. Accordingly, the serum calcium level was reduced and maintained constant over the same period, suggesting an improved therapeutic efficacy of the released drug. Nature Publishing Group UK 2017-07-17 /pmc/articles/PMC5514143/ /pubmed/28717204 http://dx.doi.org/10.1038/s41598-017-05898-6 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zhao, Ya-Nan
Xu, Xiaoyu
Wen, Na
Song, Rui
Meng, Qingbin
Guan, Ying
Cheng, Siqi
Cao, Danni
Dong, Yansheng
Qie, Jiankun
Liu, Keliang
Zhang, Yongjun
A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics
title A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics
title_full A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics
title_fullStr A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics
title_full_unstemmed A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics
title_short A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics
title_sort drug carrier for sustained zero-order release of peptide therapeutics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514143/
https://www.ncbi.nlm.nih.gov/pubmed/28717204
http://dx.doi.org/10.1038/s41598-017-05898-6
work_keys_str_mv AT zhaoyanan adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT xuxiaoyu adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT wenna adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT songrui adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT mengqingbin adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT guanying adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT chengsiqi adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT caodanni adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT dongyansheng adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT qiejiankun adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT liukeliang adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT zhangyongjun adrugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT zhaoyanan drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT xuxiaoyu drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT wenna drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT songrui drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT mengqingbin drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT guanying drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT chengsiqi drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT caodanni drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT dongyansheng drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT qiejiankun drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT liukeliang drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics
AT zhangyongjun drugcarrierforsustainedzeroorderreleaseofpeptidetherapeutics